The Canada Cancer Biomarkers Market was valued at $1075.3 Million in 2026 and projected to reach to $1777 Million by 2031, representing a compound annual growth rate of 8.7%. Canada's cancer biomarkers market is positioned for steady growth at 8.7% CAGR through 2031, driven by advancing healthcare infrastructure, increasing cancer prevalence, and widespread adoption of precision medicine diagnostics.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Canada's cancer biomarkers market is valued at $1,075.3 million in 2026 and is projected to reach $1,777.0 million by 2031, demonstrating robust expansion driven by healthcare modernization and increased cancer screening initiatives across Canadian provinces.
Canadian healthcare systems are increasingly integrating precision medicine diagnostics into oncology treatment protocols, supported by provincial health authority investments and growing physician awareness of biomarker-guided therapeutic approaches.
Canada's aging population and lifestyle factors contribute to increasing cancer incidence rates, creating sustained demand for advanced diagnostic biomarkers and early detection solutions across major metropolitan healthcare centers.
Federal and provincial funding initiatives supporting cancer research and diagnostic innovation are accelerating the adoption of next-generation biomarker testing technologies in Canadian clinical laboratories and oncology centers.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | LUNG CANCER (Cancer Type) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 11.6% from 2026 to 2031 |
| Largest Segment | OMICS TECHNOLOGIES (Profiling Technology) |
| Market Size Base Year (Billions) | ~USD 28.2 (2026) |
| Revenue Forecast (Billions) | ~USD 48.82 (2031) |
| Segments Covered | Profiling Technology, Type, Cancer Type, Products |
4 segment dimensions are covered across the global market.
| Segment | 2024 | 2025 | 2026 | 2027 | 2029 | 2030 | 2031 | 2032 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| BIOPHARMACEUTICAL COMPANIES & CROS | 234.5 | 250.7 | 271.5 | 295.1 | 352.2 | 387.9 | 429.7 | 476.3 | 9.8 |
| DIAGNOSTIC LABORATORIES | 546.6 | 576.9 | 617.1 | 662.2 | 770.4 | 837.5 | 915.7 | 1001.6 | 8.4 |
| OTHER END USERS | 40.9 | 41.7 | 42.9 | 44.3 | 47.6 | 49.6 | 51.9 | 54.3 | 4 |
| RESEARCH AND ACADEMIC INSTITUTES | 125.4 | 133.4 | 143.7 | 155.4 | 183.7 | 201.3 | 221.9 | 244.7 | 9.3 |
| TOTAL | 947.5 | 1002.6 | 1075.3 | 1157 | 1353.9 | 1476.4 | 1619.3 | 1777 | 8.7 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| NANOSTRING TECHNOLOGIES, INC | United States | ||
| CELL SIGNALING TECHNOLOGY, INC. | United States | ||
| TRANSGENOMIC, INC. | United States | ||
| SANOFI | Spain | ||
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Imaging-based biomarker systems and software,In-vitro diagnostics instruments and consumables,Varian oncology platforms and services, |
| BECTON, DICKINSON AND COMPANY | United States | Public Company | Instruments (flow cytometers, analyzers, automation),Consumables & reagents (antibodies, kits, collection products, media), |
| MYRIAD GENETICS | United States | Public Company | Hereditary cancer and germline oncology tests (e.g., MyRisk, BRACAnalysis CDx),Tumor-based prognostic and companion diagnostics (MyChoice CDx, Prolaris, EndoPredict, Precise Tumor),Other oncology-adjacent genomics and lab services within cancer workflows, |
| SYSMEX CORPORATION | Japan | Public Company | Instruments (hematology, coagulation, cell analysis platforms),Consumables (reagents, calibrators, controls, software-linked services), |
| HOLOGIC, INC. | United States | Private Company | Breast cancer imaging systems and software,Biopsy guidance systems and markers,Cytology and related consumables (ThinPrep), |
NanoString Technologies develops and commercializes molecular analysis platforms for gene expression profiling and genomic research.
Cell Signaling Technology Inc. produces research antibodies, proteins, and assay kits for cell biology and life sciences research.
Transgenomic Inc. provides genetic testing and molecular diagnostics solutions for disease detection and management.
Sanofi is a multinational pharmaceutical company developing and marketing medicines, vaccines, and diagnostic products.
Siemens Healthineers AG is a global medical technology company providing diagnostic imaging, laboratory diagnostics, and healthcare IT solutions.
Becton, Dickinson and Company manufactures and distributes medical devices, laboratory equipment, and diagnostic systems.
Myriad Genetics is a molecular diagnostics company providing genetic testing and precision medicine solutions for cancer and other diseases.
Sysmex Corporation manufactures and sells hematology, hemostasis, and clinical chemistry diagnostic systems and reagents.
Hologic Inc. develops and markets diagnostic and medical imaging systems, particularly for women's health and cancer detection.
Canada's cancer biomarkers market is estimated at $1,075.3 million in 2026.
Canada's cancer biomarkers market is forecast to reach $1,777.0 million by 2031.
Canada's cancer biomarkers market is expected to grow at a compound annual growth rate of 8.7% from 2026 to 2031.
Key drivers include Canada's aging population, increased cancer screening programs, precision medicine adoption, and strong regulatory oversight by Health Canada.
Canada represents a significant segment of the North American cancer biomarkers market, supported by robust healthcare infrastructure and genomic research investments.
The objective of the study is to analyze key market dynamics, including drivers, opportunities, restraints, challenges, and key players' strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, the competitive landscape of the cancer biomarkers market will be analyzed, and market players will be evaluated on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.
The four steps involved in estimating the market size are
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess prospects.
The following is a breakdown of the primary respondents

Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.
|
COMPANY NAME |
DESIGNATION |
|
Thermo Fisher (US) |
Sales Manager |
|
F. Hoffmann-La Roche AG (Switzerland) |
Product Manager |
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total market size of cancer biomarkers. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

After arriving at the overall market size using the process described above, the total market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Cancer biomarkers are biological molecules produced by the body or a tumor in a person with cancer. Cancer biomarker testing helps differentiate alterations in the tumor. Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer. It can also be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids. Biomarkers can be DNA, RNA, proteins, or metabolomic profiles specific to the tumor. They enhance cancer detection and facilitate high-speed, noninvasive diagnosis using profiling technologies such as omics, imaging, immunoassays, and cytogenetics.
MarketsandMarkets offers the following customizations for this market report.
Full forecast, segment splits, and company analysis for all Cancer Biomarkers Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report